Entera Bio Ltd (ENTX) - Net Assets
Based on the latest financial reports, Entera Bio Ltd (ENTX) has net assets worth $15.23 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.41 Million) and total liabilities ($2.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Entera Bio Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.23 Million |
| % of Total Assets | 87.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | 7.59% |
| 10-Year Change | N/A |
| Growth Volatility | 84.8 |
Entera Bio Ltd - Net Assets Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's net assets have evolved over time, based on quarterly financial data. See ENTX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Entera Bio Ltd (2015–2024)
The table below shows the annual net assets of Entera Bio Ltd from 2015 to 2024. For live valuation and market cap data, see Entera Bio Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.08 Million | -22.20% |
| 2023-12-31 | $10.39 Million | -11.64% |
| 2022-12-31 | $11.75 Million | -47.91% |
| 2021-12-31 | $22.57 Million | +200.47% |
| 2020-12-31 | $7.51 Million | -36.99% |
| 2019-12-31 | $11.92 Million | +17.82% |
| 2018-12-31 | $10.12 Million | +132.06% |
| 2017-12-31 | $-31.56 Million | -25.00% |
| 2016-12-31 | $-25.25 Million | +1.72% |
| 2015-12-31 | $-25.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Entera Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8451000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.01% |
| Other Comprehensive Income | $41.00K | 0.51% |
| Other Components | $121.97 Million | 1509.47% |
| Total Equity | $8.08 Million | 100.00% |
Entera Bio Ltd Competitors by Market Cap
The table below lists competitors of Entera Bio Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Minupar Participações S.A
SA:MNPR3
|
$55.03 Million |
|
Bukit Darmo Property Tbk
JK:BKDP
|
$55.04 Million |
|
CSL Finance Limited
NSE:CSLFINANCE
|
$55.06 Million |
|
Broad Capital Acquisition Corp
NASDAQ:BRAC
|
$55.09 Million |
|
Aran Research and Development 1982 Ltd
TA:ARAN
|
$55.02 Million |
|
Korea New Network Co. Ltd
KQ:058400
|
$55.01 Million |
|
Epitomee Medical Ltd
TA:EPIT
|
$55.00 Million |
|
Rent.com.Au Ltd
AU:RNT
|
$55.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Entera Bio Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,386,000 to 8,080,000, a change of -2,306,000 (-22.2%).
- Net loss of 9,541,000 reduced equity.
- New share issuances of 3,960,000 increased equity.
- Other factors increased equity by 3,275,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.54 Million | -118.08% |
| Share Issuances | $3.96 Million | +49.01% |
| Other Changes | $3.27 Million | +40.53% |
| Total Change | $- | -22.20% |
Book Value vs Market Value Analysis
This analysis compares Entera Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-2.16 | $1.20 | x |
| 2016-12-31 | $-2.12 | $1.20 | x |
| 2017-12-31 | $-2.65 | $1.20 | x |
| 2018-12-31 | $0.88 | $1.20 | x |
| 2019-12-31 | $0.98 | $1.20 | x |
| 2020-12-31 | $0.41 | $1.20 | x |
| 2021-12-31 | $0.86 | $1.20 | x |
| 2022-12-31 | $0.41 | $1.20 | x |
| 2023-12-31 | $0.36 | $1.20 | x |
| 2024-12-31 | $0.21 | $1.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Entera Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -118.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5271.27%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.16x
- Recent ROE (-118.08%) is below the historical average (-69.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.71 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $1.33 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.04 Million |
| 2018 | -101.86% | -2060.80% | 0.04x | 1.32x | $-11.32 Million |
| 2019 | -90.57% | -4574.15% | 0.01x | 1.40x | $-11.99 Million |
| 2020 | -132.93% | -2735.07% | 0.04x | 1.29x | $-10.73 Million |
| 2021 | -54.01% | -2134.33% | 0.02x | 1.15x | $-14.44 Million |
| 2022 | -111.20% | -9754.48% | 0.01x | 1.12x | $-14.25 Million |
| 2023 | -85.59% | -63492.86% | 0.00x | 1.13x | $-9.93 Million |
| 2024 | -118.08% | -5271.27% | 0.02x | 1.16x | $-10.35 Million |
Industry Comparison
This section compares Entera Bio Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Entera Bio Ltd (ENTX) | $15.23 Million | 0.00% | 0.14x | $55.03 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more